Позитронная эмиссионная томография в онкоурологической практике

1. Cremerius U., Effert P.J., Adam G. et al. FDG PET for detection and therapy control of metastatic germ cell tumour // J. Nucl. Med. — 1998;39:815—822.

2. Hoh C.K., Seltzer M.A., Franklin F.J. et al. Positron emission tomography in urologic oncology // J. Urol. — 1998;159:347—356.

3. Liu I.J., Zafar M.B., Lai Y.H. et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer // Urology. — 2001;57:108—111.

4. Ramdave S.,Thomas G.W., Berlangieri S.U. et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma // J. Urol. — 2001;166:825— 830.

5. Oyama N., Akino H., Suzuki Y. et al. The increased accumulation of 18[F]fluorodeoxyglucose in untreated prostate cancer // Jpn. J. Clin. Oncol. — 1999;29:623—629.

6. Heicappell R., Muller-Mattheis V., Reinhardt M. et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose // Eur. Urol. — 1999;36:582—587.

7. Sanz G., Robles J.E., Gimenez M. et al. Positron emission tomography with 18fluorine-labeled deoxyglucose: utility in localized and advanced prostate cancer // Br. J. Urol. — 1999;84:1028—1931.

8. Seltzer M.A., Barbaric Z., Belldegrun A. Comparison of helical computerized tomography, positron emission tomography, and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer // J. Urol. — 1999;162:1322—1328.

9. Nunez R., Macapinlac H.A., Yeung H.W. et al. Combined 18F-FDG and 11C-methionine PET Scans in patients with newly progressive metastatic prostate cancer // J. Nucl. Med. — 2002;43:46—55.

10. Sung J., Espiritu J.I., Segall G.M. et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically advanced prostate cancer // BJU International. — 2003; 92:24—27.

11. Schirrmeister H., Guhlmann A., Elsner K. et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET // J. Nucl. Med. — 1999;40:1623—1629.

12. Hoh C.K., Figlin R., Belldegrun A. Evaluation of renal cell carcinoma with whole body FDG PET // J. Nucl. Med. — 1996;37:141P.

13. Bachor R., Kotzerke J., Gottfried H.W. Positron emission tomography in diagnosis of renal cell carcinoma [German].— Urologe A. — 1996;35:146—150.

14. Weber W.A., Avril N., Schwaiger M. Relevance of Positron Emission Tomography (PET) in Oncology // J. Strahlenther Onkol. — 1999; № 8, Vol. 175. — P.356—373

15. Kocher F., Grimmel S., Hautmann R. et al. Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm // J. Nucl. Med. — 1994;35(suppl):233P.

16. Safaei A., Figlin R., Hoh C.K. et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer // Clin. Nephrol. — 2002;57:56—62.

17. Seto E., Segall G.M., Terris M.K. Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan // Urology. — 2000;55:286.

18. Albers P., Bender H., Yilmaz H. et al. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors // Urology. — 1999;53:808—811.

19. Badjorin D.F., Herr H., Motzer R.J. et al. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors Semin oncol 19. —1992: P. 148—158.

20. Cremerius U., Wildberger J.E., Borchers H. et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients // Urology. — 1999;54:900—904.

21. Ganjoo K.N., Chan R.J., Sharma M. et al. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma // J. Clin. Oncol. — 1999;17:3457—3460.

22. Nuutinen J., Leskinen S., Elomaa I. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. // Eur. J. Cancer. — 1997;33:1234—1241.

23. Puc H.S., Heelan R., Mazumdar M. et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial SloanKettering Cancer Center // J. Clin. Oncol. 1996;14: 454—460.

24. Schultz S.M., Einhorn L.H., Conces D.H. Jr. et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience // J. Clin. Oncol. — 1989;7:1497—1503.

25. Shreve P.D., Grossman H.B., Gross M.D. et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[18F]fluoro-D-glucose // Radiology. — 1996. — № 199. — P. 751—756.